[Secondary candidal infection in patients with chronic dermatoses].
Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%). C. albicans, often associated with bacillary (33.3%) or bacterial (7.3%) microflora, predominated among the yeast-like fungi isolated from the patients. These data point to the necessity of prescribing, besides the antimycotic agents, a complex of pathogenetic therapy including immunomodulators, in order to cut down the terms of treatment and prevent secondary candidal infection in the patients with chronic dermatoses.
Dovzhanskiĭ
S I
SI
Orkin
V F
VF
Myshkina
A K
AK
Pavlenko
L B
LB
D000293:Adolescent; D000328:Adult; D000368:Aged; D000917:Antibody Formation / Q000276:immunology; D002175:Candida / Q000187:drug effects / Q000302:isolation & purification; D002177:Candidiasis / Q000209:etiology*; D002178:Candidiasis, Chronic Mucocutaneous / Q000209:etiology* / Q000276:immunology / Q000382:microbiology; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D012871:Skin Diseases / Q000150:complications* / Q000276:immunology / Q000382:microbiology
Vtorichnaia kandidoznaia infektsiia u bol'nykh khronicheskimi dermatozami.